---
title: "BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297310247.md"
datetime: "2026-08-28T10:41:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297310247.md)
  - [en](https://longbridge.com/en/news/297310247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297310247.md)
generator: "portal-rs"
---

# BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study

Shares of drugmaker Cytokinetics (CYTK.O) rise 1.7% to $79.27 premarket CYTK says detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments

The drug is already approved as Myqorzo for oHCM — the obstructive form of the condition called hypertrophic cardiomyopathy in which thickened heart muscles block ​blood flow Myqorzo competes with Bristol Myers Squibb’s (BMY.N) Camzyos in the oHCM segment

The company is seeking to expand its use to the non-obstructive form (nHCM), which causes heart muscle thickening without blocking blood flow

As of last close, CYTK stock was up 22.6% YTD

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [Cytokinetics (CYTK) Shares In Focus After New Phase 3 Aficamten Data](https://longbridge.com/en/news/298814945.md)
- [CYTK: MYQORZO drives growth with strong launches, robust pipeline, and expanding global reach](https://longbridge.com/en/news/298495700.md)
- [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110](https://longbridge.com/en/news/298363335.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**